Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

The prostate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.99 billion in 2025 to $1.13 billion in 2026 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to expansion of nuclear medicine infrastructure, increased use of radiotracers in oncology, availability of gamma camera and pet imaging systems, rising prostate cancer diagnosis rates, growth in hospital-based imaging services.

The prostate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.84 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to advancements in radiopharmaceutical development, rising demand for precise cancer staging tools, expansion of personalized oncology diagnostics, increasing investment in hybrid imaging platforms, growing adoption of molecular imaging techniques. Major trends in the forecast period include increasing adoption of pet and spect imaging modalities, rising use of radiopharmaceutical-based diagnostics, growing demand for functional cancer imaging, expansion of hybrid imaging technologies, enhanced focus on accurate disease staging.

The increasing prevalence of prostate cancer is expected to drive the growth of the prostate cancer nuclear medicine diagnostics market in the coming years. Prostate cancer is a form of cancer that develops in the prostate, a small walnut-shaped gland in males responsible for producing seminal fluid that nourishes and transports sperm. The rising incidence of prostate cancer is attributed to factors such as an aging population, lifestyle changes, and genetic predisposition. Prostate cancer nuclear medicine diagnostics offer critical insights that allow clinicians to provide more accurate, effective, and personalized treatment for patients with prostate cancer. For instance, in February 2024, according to the World Health Organization, a Switzerland-based specialized agency for international public health, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared with the estimated 20 million cases in 2022. Therefore, the growing prevalence of prostate cancer is driving the prostate cancer nuclear medicine diagnostics market.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are focusing on the development of advanced approaches such as targeted alpha-particle radiotherapy to improve treatment precision while reducing damage to healthy tissue. Targeted alpha-particle radiotherapy utilizes radioactive isotopes that emit alpha particles to selectively destroy cancer cells, offering a highly localized and effective therapeutic option. For instance, in March 2025, Actinium Pharmaceuticals Inc., a US-based developer of antibody radiation conjugates and targeted radiotherapies, launched ATNM-400 featuring actinium-225 radiotherapy. This therapy targets a non-prostate-specific membrane antigen that is overexpressed in prostate cancer patients and provides an alternative option for individuals who are resistant to PSMA-targeted therapies such as Pluvicto. Key characteristics of ATNM-400 include the use of the alpha-particle emitter actinium-225, which helps reduce off-target effects compared with beta-particle therapies, and its focus on a distinct cancer marker to expand treatment applicability. The launch was supported by preclinical data demonstrating biodistribution, imaging performance, and efficacy across multiple dose levels, with additional findings expected from Pluvicto-resistant prostate cancer models. ATNM-400 is positioned to advance precision radiotherapy and improve treatment options for prostate cancer patients.

In March 2023, Life Healthcare Group, a South Africa-based healthcare company, acquired TheraMed Nuclear for an undisclosed amount. Through this acquisition, Life Healthcare strengthened its diagnostic imaging capabilities, particularly in the detection and treatment of conditions such as organ dysfunction and cancer. TheraMed Nuclear is a South Africa-based company that provides prostate cancer nuclear medicine diagnostic services.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, Curium Pharma, Telix Pharmaceuticals Ltd, Eckert And Ziegler AG, Point Biopharma Global Inc, Alliance Medical Ltd, SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Isotope Technologies Garching ITG, Jubilant Pharma Limited, Blue Earth Diagnostics Inc, Institute Of Isotopes Co Ltd, Radiopharm Theranostics, Bracco Diagnostic Inc, NCM USA LLC, ABX Advanced Biochemical Compounds GmbH, Theragnostics Ltd, SpectronRx Inc.

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2025. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the prostate cancer nuclear medicine diagnostics market by increasing costs of imported imaging equipment, radiopharmaceutical precursors, detector components, and advanced software systems used in PET and SPECT platforms. Healthcare providers in North America and Europe are most affected due to reliance on imported nuclear imaging technologies, while Asia-Pacific faces cost escalation in equipment manufacturing and radioisotope sourcing. These tariffs increase capital expenditure and operational costs for imaging centers. However, they are also driving domestic production of imaging components, regional radiopharmaceutical development, and investment in localized nuclear medicine capabilities.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prostate cancer nuclear medicine diagnostics involve the use of radioactive substances to identify and assess prostate cancer. These diagnostic methods support the detection, staging, and management of prostate cancer by delivering detailed functional insights into the disease’s extent and characteristics. This approach uses radiopharmaceuticals that are administered into the body, most commonly through injection, and emit gamma rays or positrons for imaging purposes.

The primary types of prostate cancer nuclear medicine diagnostics include single photon emission computed tomography (SPECT) and positron emission tomography (PET). Single photon emission computed tomography is a nuclear imaging technique that produces detailed three-dimensional images of functional processes within the body. The different test categories include preliminary and confirmatory tests, and these diagnostics are utilized by end users such as hospitals, clinics, and other healthcare facilities.

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.